Research Background

This study was initiated to identify immune defects in patients experiencing recurrent or unusual infections and their families. Immune deficiencies increase infection risk and limit therapeutic options, making early diagnosis and precise etiologic identification critical. Because the study is overseen by NIAID, it holds significant public‑health relevance.

Clinical Design

Patients and family members are followed longitudinally, with regular collection of diverse biospecimens—including blood, urine, saliva, skin swabs, stool, and wound fluid. Participants visit the study site at least every six months for updates to medical records and examinations, and, when indicated, undergo genetic testing and biomarker analyses. The study began in 1993, continues to enroll participants, and has no defined end date.

Current Therapeutic Landscape

Congenital immune deficiencies, including phagocytic dysfunction, often rely on antibiotic therapy, while disease‑modifying treatments are limited. Standard care focuses on symptom management, leaving patients vulnerable to recurrent infections. Consequently, pinpointing the exact genetic and biochemical causes can serve as a launch point for novel therapeutic development.

Industry and Research Impact

The genetic and biomarker data generated by this study are highly valuable for diagnostic‑kit development and the research of personalized immune therapies. Pharmaceutical and biotech companies can leverage these data to expand pipelines for rare immune disorders and to inform clinical trial design. Additionally, the project may catalyze collaborative models between public research institutions and industry.